Proposed crystal structure of cabotegravir, C 19 H 17 F 2 N 3 O 5
Source abstract
Abstract
Abstract The crystal structure of cabotegravir has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Cabotegravir crystallizes in space group P2 1 2 1 2 (#18) with a = 31.4706(11), b = 13.4934(3), c = 8.43811(12) Å, V = 3,583.201(18) Å 3 , and Z = 8 at 298 K. The crystal structure consists of stacks of roughly parallel molecules along the c -axis. The molecules form layers parallel to the bc -plane. O–H···O hydrogen bonds link one of the two independent molecules into chains along the b -axis. The powder pattern has been submitted to the International Centre for Diffraction Data (ICDD ® ) for inclusion in the Powder Diffraction File ™ (PDF ® ).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Crystallization and Solubility Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Illinois Institute of Technology
North Central College
International Centre for Diffraction Data (ICDD)
Funding
International Centre for Diffraction Data
References (38)
Show source-provided references
1. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
2. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
3. A New Law of Crystal Morphology Extending the Law of Bravais
4. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
5. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
6. 2023
7. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
8. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
9. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
10. 10.1107/S010876810000723010.1107/S0108768100007230 ↗
11. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
12. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
13. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
14. 2013
15. 2024
16. 10.1017/S088571562400015010.1017/S0885715624000150 ↗
17. Wang, H. , Goodman, S. N. , Mans, D. , and Kowalski, M. . 2011. “Process for Preparing Carbamoylpyridone Derivatives and Intermediates.” International Patent Application WO 2011/119566 A1.
18. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
19. 2024
20. 10.1107/S160057752100249610.1107/S1600577521002496 ↗
21. 10.1021/ci049780b10.1021/ci049780b ↗
22. 10.1107/S002188980201523610.1107/S0021889802015236 ↗
23. 10.1063/1.46788210.1063/1.467882 ↗
24. 10.1107/S002188989800600110.1107/S0021889898006001 ↗
25. 10.1524/zksu.2007.2007.suppl_26.19110.1524/zksu.2007.2007.suppl_26.191 ↗
26. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
27. 10.1016/j.biomaterials.2017.10.02310.1016/j.biomaterials.2017.10.023 ↗
28. 10.1002/jcc.2315310.1002/jcc.23153 ↗
29. 2023
30. Adamer, V. , and Thaler, A. . 2017. “Crystalline Form of Cabotegravir Sodium.” European Patent Specification EP 3363802 B1.
31. 10.1017/S143192761901044410.1017/S1431927619010444 ↗
32. 2023
33. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
34. 10.1007/BF0054909610.1007/BF00549096 ↗
35. 10.1002/anie.19951555110.1002/anie.199515551 ↗
36. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
37. Bravais · 1866
38. 10.1021/ar00172a00510.1021/ar00172a005 ↗